title: [Comparison of intrapleural OK-432 and cisplatin for malignant pleural effusion in lung cancer patients].
abstract: Malignant pleural effusion is typical of complications in advanced lung cancer patients, most of whom complain of dyspnea. The standard treatment for symptomatic pleural effusion is intrapleural administration of a chemical agent. In Japan, OK-432, a streptococcal preparation, and cisplatin (CDDP) have been among the most frequently used chemical agents. There have been very few reports on the efficacy of chemical agents for malignant pleural effusion. We compared therapeutic efficacy and toxicity of intrapleural OK-432 with CDDP in a case-control study. The subjects consisted of 32 lung cancer patients with malignant pleural effusion who were admitted to our hospital between January 2000 and June 2004. The therapeutic efficacy was assessed from duration of chest drainage after intrapleural administration, response rate, time to progression of malignant pleural effusion, and survival time. No statistically significant difference was observed for therapeutic efficacy. Although the OK-432-treated group had only grade 1 fever, chest pain, nausea, the CDDP-treated group had a grade 2 increase in creatinine and grade 3 nausea. Intrapleural OK-432 seemed to be better tolerated in the treatment of malignant pleural effusion than intrapleural CDDP.
authors.affiliation: Dept of Respiratory Medicine, Nihon University School of Medicine.
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Shimizu
authors.forename: Noriaki
authors.initials: N
authors.lastname: Takahashi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Terakado
authors.forename: Maki
authors.initials: M
authors.lastname: Sato
authors.forename: Toshio
authors.initials: T
authors.lastname: Sugane
authors.forename: Akira
authors.initials: A
authors.lastname: Kisohara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Akusawa
authors.forename: Ichiro
authors.initials: I
authors.lastname: Tsujino
authors.forename: Takashi
authors.initials: T
authors.lastname: Horie
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000633:toxicity; D016022:Case-Control Studies; D002945:Cisplatin / Q000008:administration & dosage* / Q000633:toxicity; D018450:Disease Progression; D004322:Drainage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000008:administration & dosage* / Q000633:toxicity; D035422:Pleural Cavity; D016066:Pleural Effusion, Malignant / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D010844:Picibanil; D002945:Cisplatin